VerityRank
Yukiguni Maitake Co., Ltd.
Brand VerifiedJapan

Yukiguni Maitake Co., Ltd.

Yukiguni Maitake

Yukiguni Maitake Co., Ltd. is a Japanese cultivator and processor of speciality mushrooms that sells under the consumer brand Yukiguni Maitake. Its head office is in Minamiuonuma, Niigata Prefecture, the snow-country district that gave the company its name and where most of its growing capacity still sits. The business was founded in 1983 and is listed on the Prime Market of the Tokyo Stock Exchange under the code 1375, one of four exchange-listed growers among the ten companies on this page. Yukiguni Maitake Co., Ltd. is not a Fortune Global 500 company: revenue of about JPY 48.2 billion, or roughly US$320 million, in the 2025/2026 financial year is about one per cent of the approximately US$32.2 billion threshold applied for the 2025 list, and no shareholder of the company is a member of it.

The company's identity rests on a single species. Maitake is harder to fruit indoors at industrial scale than button mushrooms or enoki, and sterile artificial cultivation technology for the species is what turned Yukiguni Maitake from a regional grower into the leading supplier of maitake in Japan. That technical lead is also why the species still commands a premium at retail, and why the company's margins have depended more on mix than on volume. King oyster and brown beech mushrooms and processed health-food products widen the base, but the premium still rests on maitake.

Revenue for the 2025/2026 financial year is JPY 48.2 billion, approximately US$320 million, of which mushrooms account for about 94% and processed food lines for the remainder. Output runs at around 55,000 tonnes a year from eleven modern fruiting and processing plants, most of them in and around Niigata Prefecture. About 1,150 people are employed across the group, small against the tonnage, reflecting heavily automated growing rooms. The company reports operations in three countries and regions, Japan dominant among them, and sells roughly 45% of its non-maitake mushroom lines overseas.

Founded in 1983 in a region whose cold winters and clean water suit controlled cultivation, the company grew from a local producer into a national supplier and then into a listed business. It has kept cultivation and processing close together in Niigata rather than dispersing them across contract farms, which is expensive to build and slow to copy, and that is why the position has proved defensible. The same choice leaves the group carrying Japanese energy, materials and labour costs in full, with no low-cost offshore base to offset them.

Trading in the 2025/2026 year has been about price rather than volume. Shipping prices for the company's mushrooms stabilised and then began to recover in the second quarter, and management has worked the retail side of the business by promoting small, high-freshness packs and a wider range of cooking suggestions, including promotional partnerships with social media influencers. Those measures raise the value of a fixed harvest rather than requiring a larger one. Investment continues in automation, sterile cultivation research and processed health-food lines built on maitake extracts.

Cost inflation is the immediate problem. Sawdust and nutrient substrates are largely bought in, freight charges have risen, and together they have pressed core EBITDA year on year; the company has responded with manufacturing cost reduction and flexible control of production volumes rather than with price increases that a price-sensitive domestic market may not accept. The longer-term exposure is the premium itself: if maitake loses its speciality status, or if larger commodity growers replicate sterile cultivation and add capacity, the pricing advantage that supports the whole position narrows.

Read More
JapanFounded 1983~1,150JPY$48.2 B / ~US$320m11 fruiting and processing… / 100
Listed onTSE1375
Last updated: 2026-11-20 01:30 ET·By VerityRank Research Team·Methodology

Listed market data

1375 · TSE · weeklyHistory →
Market cap
$286 M
Share price
JPY 1142.00
1Y change
+8.5%
Recent change
+0.4%

11-19 → 11-20

Since first close
-45.4%

from 2020-09

Revenue (TTM)
JPY$48.2 B / ~US$320m (FY2025/2026); mushrooms ~94%
· updated 2026-11-20 01:30 ETSource ↗

Financial history

Full market history
JPY 0$0JPY 375$75.0 MJPY 750$150 MJPY 1,125$225 MJPY 1,500$300 M2025-122026-012026-022026-032026-042026-052026-062026-072026-082026-092026-102026-11
MonthCloseMarket capChange
  • 2026-11JPY 1142.00$286 M+1.2%
  • 2026-10JPY 1128.00$282 M-2.7%
  • 2026-09JPY 1159.00$290 M-2.2%
  • 2026-08JPY 1185.00$297 M+1.6%
  • 2026-07JPY 1166.00$292 M+3.5%
  • 2026-06JPY 1127.00$282 M+7.3%
  • 2026-05JPY 1050.00$263 M0.0%
  • 2026-04JPY 1050.00$263 M-2.1%
  • 2026-03JPY 1072.00$268 M-2.7%
  • 2026-02JPY 1102.00$276 M+3.8%
  • 2026-01JPY 1062.00$266 M+1.0%
  • 2025-12JPY 1052.00$263 M—
Monthly closes · 2025-12 – 2026-11 · Full market history

Ownership & Control

Latest available filings
Controlling entity
Publicly held — no controlling shareholder disclosed
Company type
Brand
Insiders
50.24%
Institutions
8.08%(27 holders)
Free float
16.24%

Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.

Yukiguni Maitake is the Japanese specialist that turned maitake into a factory-grown premium mushroom and still leads its home market in the species. It ranks eighth here on about US$320 million of revenue for the 2025/2026 financial year, with roughly 1,150 employees and eleven plants concentrated in Niigata Prefecture.

Industry Position

Maitake sits in a different price band from button mushrooms or enoki, and the company's position rests on being the established supplier of it in Japan. Sterile artificial cultivation at industrial scale is the capability behind that position; few growers have matched it, and it keeps the business out of the commodity volume competition that defines most of the world's mushroom industry.

Yukiguni Maitake is one of four exchange-listed businesses on this page, quoted on the Tokyo Stock Exchange Prime Market, with about 94% of revenue from mushrooms and the rest from processed health-food products. Capacity of roughly 55,000 tonnes a year from eleven fruiting and processing sites is small against the Chinese industrial growers, but the mix is far richer. Brand heat in this study's assessment is 85 out of 100.

Competitive Advantages

The technique is the first advantage. Maitake was a wild forest mushroom before growers learned to fruit it indoors, and sterile cultivation is why the species can now be supplied reliably at scale. That barrier protects pricing in a way a commodity portfolio cannot: buyers who want Japanese maitake have a short list of suppliers, and this company sits at the top of it.

Concentration in Niigata is the second. The region's cool climate and clean water suit controlled cultivation, and keeping fruiting and processing plants close together shortens the distance between harvest and pack. The trade is deliberate: proximity and control in exchange for exposure to a single national energy, materials and labour market, with no offshore base to fall back on.

Strategic Expansion

The 2025/2026 strategy has been commercial rather than industrial. Shipping prices for the company's mushrooms stabilised and began to recover in the second quarter, and management pushed small, high-freshness pack formats and a broader set of cooking suggestions at retail, including work with social media influencers to reach consumers who do not habitually buy mushrooms.

Overseas, the group operates in three countries and regions with Japan dominant, and about 45% of its non-maitake mushroom lines are sold abroad, so international sales are a meaningful but secondary channel rather than the growth engine. Investment continues in automation and cultivation research, and processed health-food lines built on maitake extracts extend the portfolio beyond fresh produce.

Risks & Outlook

Input costs are pressing on profitability. Sawdust and nutrient substrate are bought in and freight rates have risen, squeezing core EBITDA year on year; the company has chosen manufacturing cost reduction and flexible control of production volumes over price increases it may not be able to hold at retail. Almost all revenue is domestic, so yen-denominated costs cannot be offset with overseas earnings at scale.

The longer-term risk is the premium itself. If maitake loses its speciality status, or if larger growers replicate sterile cultivation and add capacity, the pricing advantage that supports the whole position would narrow. Yukiguni Maitake Co., Ltd. is not a Fortune Global 500 company: about US$320 million of revenue is roughly one per cent of the approximately US$32.2 billion threshold applied for the 2025 list, and no investor in the company is a member of it. VerityRank Score of 79/100.

Quick Facts

Headquarters

Minamiuonuma, Niigata Prefecture, Japan

Founded

1983 (Niigata Prefecture, Japan)

Employees

~1,150 (FY2025/2026)

Revenue

JPY$48.2 B / ~US$320m (FY2025/2026); mushrooms ~94%

Market cap

$286 M

Factories

11 fruiting and processing plants, mainly in Niigata Prefecture

Presence

3 countries and regions; Japan dominant

Listing

Tokyo Stock Exchange Prime: 1375
Categories

Related

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website , Corporate Site · Q2 FY2025/26 Results · Mushroom Market 2026 · Functional Mushroom Market · Fresh Mushroom 2035